Le point en 1999 sur la Tibolone
Rev Med Suisse
2000; volume -4.
20567
Résumé
La tibolone est une substance présentant des effets strogéniques et progestatifs sans effets sur la glande mammaire et l'endomètre. Elle est efficace dans la prévention de la perte osseuse post-ménopausique.
Bibliographie
Bibliographie
1 Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997 ; 337 : 1641-7.
2 Delmas PD, Ensrud KE, Harris S, et al. Raloxifene therapy for 3 years reduces the risk of incident vertebral fractures in postmenopausal women. Calc Tiss Int 1999 ; 64 (Suppl.1) : abstract O-27.
3 Markiewicz L, Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestogenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem 1990 ; 35 : 535-41.
4 Klosterboer HJ : Tibolone and its metabolites : Pharmacology, tissue specificity and effects in animal models of tumors. Gynecol Endocrinol 1997 ; 11 (Suppl. 1) : 63-9.
5 McClung MR. New data on oral 17b - estradiol + NETA in prevention of postemenopausal bone loss. New Combination alternatives in HRT, a satellite symposium. Europ Congress Osteoporosis Berlin, 1998.
6 Genant HK, Lucas J, Weiss St, et al. Low-dose esterified estrogen therapy. Arch Intern Med 1997 ; 157 : 2609-15.
7 Ginsburg J. Tibolone and the endometrium tibolone and bleeding. J Menopause 1999 ; 1 (Suppl. 1) : 9-12.
8 Hammar M, et al. A double-blind, randomized trial comparing the effect of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998 ; 105 : 904-11.
9 Lippuner K, et al. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17b-Estradiol and dydrogesterone. J Bone Miner Res 1997 ; 12 : 806-12.
10 Ginsburg J, Prelevic G, Butler D, Okolo S. Clinical experience with tibolone (Livial ®) over 8 years. Maturitas 1995 ; 21 : 71-6.
11 Bjarnason NH, et al : Tibolone : Prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996 ; 81 : 2419-22.
12 Berning B, Kuijk CV, Kuiper JW, Coelingh Bennink HJT, Kicovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women : A two-year randomized, placebo-controlled stu-
dy. Bone 1996 ; 19 : 395-9.
13 Rymer J, et al. Effect of tibolone on postmenopausal bone loss. Osteoporos Int 1994 ; 4 : 314-9.
14 Thiébaud D, Bigler JM, Rentereia S, et al. A 3-year study of prevention of postmenopausal bone loss : Conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Climateric 1998 ; 1 : 202-10.
15 Prevelic GM, et al. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Gynecol Endocrinol 1996 ; 10 : 413-20.
16 The Writing Group of the PEPI trial. Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. Effects of hormone therapy on bone mi-neral density. JAMA 1996 ; 276 : 1389-96.
17 Eriksen EF, et al. European and North American experience with HRT for the prevention of osteoporosis. Bone 1996 ; 19 : 179S-83S.
18 Studd J, et al. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998 ; 92 : 574-9.
19 Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991 ; 13 : 155-62.
20 Hänggi W, Lippuner K, Riesen W, Jaeger P, Birkhäuser MH. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a) : A randomized trial. Br J Obstet Gynaecol 1997 ; 104 : 708-17.
Pour revue : Moore RA. Livial : A review of clinical studies. Br J Obstet Gynaecol 1999 ; 106 (Suppl. 19): 1-21.
1 Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997 ; 337 : 1641-7.
2 Delmas PD, Ensrud KE, Harris S, et al. Raloxifene therapy for 3 years reduces the risk of incident vertebral fractures in postmenopausal women. Calc Tiss Int 1999 ; 64 (Suppl.1) : abstract O-27.
3 Markiewicz L, Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestogenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem 1990 ; 35 : 535-41.
4 Klosterboer HJ : Tibolone and its metabolites : Pharmacology, tissue specificity and effects in animal models of tumors. Gynecol Endocrinol 1997 ; 11 (Suppl. 1) : 63-9.
5 McClung MR. New data on oral 17b - estradiol + NETA in prevention of postemenopausal bone loss. New Combination alternatives in HRT, a satellite symposium. Europ Congress Osteoporosis Berlin, 1998.
6 Genant HK, Lucas J, Weiss St, et al. Low-dose esterified estrogen therapy. Arch Intern Med 1997 ; 157 : 2609-15.
7 Ginsburg J. Tibolone and the endometrium tibolone and bleeding. J Menopause 1999 ; 1 (Suppl. 1) : 9-12.
8 Hammar M, et al. A double-blind, randomized trial comparing the effect of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998 ; 105 : 904-11.
9 Lippuner K, et al. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17b-Estradiol and dydrogesterone. J Bone Miner Res 1997 ; 12 : 806-12.
10 Ginsburg J, Prelevic G, Butler D, Okolo S. Clinical experience with tibolone (Livial ®) over 8 years. Maturitas 1995 ; 21 : 71-6.
11 Bjarnason NH, et al : Tibolone : Prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996 ; 81 : 2419-22.
12 Berning B, Kuijk CV, Kuiper JW, Coelingh Bennink HJT, Kicovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women : A two-year randomized, placebo-controlled stu-
dy. Bone 1996 ; 19 : 395-9.
13 Rymer J, et al. Effect of tibolone on postmenopausal bone loss. Osteoporos Int 1994 ; 4 : 314-9.
14 Thiébaud D, Bigler JM, Rentereia S, et al. A 3-year study of prevention of postmenopausal bone loss : Conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Climateric 1998 ; 1 : 202-10.
15 Prevelic GM, et al. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Gynecol Endocrinol 1996 ; 10 : 413-20.
16 The Writing Group of the PEPI trial. Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. Effects of hormone therapy on bone mi-neral density. JAMA 1996 ; 276 : 1389-96.
17 Eriksen EF, et al. European and North American experience with HRT for the prevention of osteoporosis. Bone 1996 ; 19 : 179S-83S.
18 Studd J, et al. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998 ; 92 : 574-9.
19 Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991 ; 13 : 155-62.
20 Hänggi W, Lippuner K, Riesen W, Jaeger P, Birkhäuser MH. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a) : A randomized trial. Br J Obstet Gynaecol 1997 ; 104 : 708-17.
Pour revue : Moore RA. Livial : A review of clinical studies. Br J Obstet Gynaecol 1999 ; 106 (Suppl. 19): 1-21.
